PMID- 32450563
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 1421-9875 (Electronic)
IS  - 0257-2753 (Linking)
VI  - 39
IP  - 1
DP  - 2021
TI  - Risk Factors for Adverse Events in Patients with Chronic Constipation Following 
      Lubiprostone Administration.
PG  - 10-15
LID - 10.1159/000508864 [doi]
AB  - INTRODUCTION: Lubiprostone is an effective treatment of chronic constipation 
      (CC). However, as with other stimulant or osmotic laxatives, adverse events (AEs) 
      can make it difficult to continue treatment. This article investigates AE risk 
      factors associated with lubiprostone. METHODS: We retrospectively analyzed all 
      1,338 Japanese patients with CC treated at our hospital from October 2013 to July 
      2017. All patients were diagnosed with constipation as defined by the Roma III 
      criteria. Enrolled patients received lubiprostone orally (24 or 48 mug daily), 
      after which we investigated the incidence of AEs. The causative factors for 
      diarrhea and nausea, the most common AEs, were examined by the backward logistic 
      regression model. RESULTS: Two hundred eight (15.5%) experienced at least 1 AE. 
      No serious AEs were associated with the study drug. The AEs reported by >1% of 
      patients overall were diarrhea (6.1%) and nausea (4.2%). We performed a 
      multivariate logistic regression using a backward variable selection method to 
      investigate AE risk factors. Factors associated with higher incidence of diarrhea 
      were patient age of 65 years or more (odds ratio: [95% confidence interval]; p 
      value) (2.09: [1.05-4.16]; 0.035). Factors associated with greater likelihood of 
      nausea included female gender (1.99: [1.10-3.61]; 0.023), and the chief complaint 
      was a patient complaining of abdominal pain and fullness (2.07: [1.01-4.22]; 
      0.046). CONCLUSIONS: Understanding AE risk factors can help avoid unnecessary AEs 
      and promote more effective treatment.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Eguchi, Takaaki
AU  - Eguchi T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan, egugu0515@yahoo.co.jp.
FAU - Yoshizaki, Tetsuya
AU  - Yoshizaki T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Takagi, Megumi
AU  - Takagi M
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Ikeoka, Seitaro
AU  - Ikeoka S
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Hashimura, Hiroki
AU  - Hashimura H
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Okamoto, Norihiro
AU  - Okamoto N
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Matsumoto, Masanori
AU  - Matsumoto M
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Matsuda, Tatsuya
AU  - Matsuda T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Miura, Takahiro
AU  - Miura T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Momose, Kenji
AU  - Momose K
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Otsuka, Takashi
AU  - Otsuka T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Morisawa, Toshiyuki
AU  - Morisawa T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Okada, Akihiko
AU  - Okada A
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - Switzerland
TA  - Dig Dis
JT  - Digestive diseases (Basel, Switzerland)
JID - 8701186
RN  - 7662KG2R6K (Lubiprostone)
SB  - IM
MH  - Aged
MH  - Chronic Disease
MH  - Constipation/*drug therapy
MH  - Feces
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Lubiprostone/administration & dosage/*adverse effects/*therapeutic use
MH  - Male
MH  - Multivariate Analysis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse event
OT  - Constipation
OT  - Diarrhea
OT  - Lubiprostone
OT  - Nausea
EDAT- 2020/05/26 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/05/26 06:00
PHST- 2019/11/02 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - 000508864 [pii]
AID - 10.1159/000508864 [doi]
PST - ppublish
SO  - Dig Dis. 2021;39(1):10-15. doi: 10.1159/000508864. Epub 2020 May 25.